EA202090917A1 - OBTAINING PSILOCYBIN, DIFFERENT POLYMORPHOUS FORMS, INTERMEDIATE COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION - Google Patents

OBTAINING PSILOCYBIN, DIFFERENT POLYMORPHOUS FORMS, INTERMEDIATE COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION

Info

Publication number
EA202090917A1
EA202090917A1 EA202090917A EA202090917A EA202090917A1 EA 202090917 A1 EA202090917 A1 EA 202090917A1 EA 202090917 A EA202090917 A EA 202090917A EA 202090917 A EA202090917 A EA 202090917A EA 202090917 A1 EA202090917 A1 EA 202090917A1
Authority
EA
Eurasian Patent Office
Prior art keywords
psilocybin
compositions
obtaining
application
intermediate compounds
Prior art date
Application number
EA202090917A
Other languages
Russian (ru)
Inventor
Дерек Джон Лондебро
Кристофер Браун
Джилиан Скотт Нортен
Джиллиан Мур
Хемант Патил
Дэвид Николс
Original Assignee
Компасс Патфайндер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60326674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090917(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Компасс Патфайндер Лимитед filed Critical Компасс Патфайндер Лимитед
Publication of EA202090917A1 publication Critical patent/EA202090917A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к крупномасштабному производству псилоцибина для применения в медицине. Более конкретно, оно относится к способу получения высокой чистоты кристаллического псилоцибина, в частности в форме полиморфа A. Оно также относится к способу производства псилоцибина и промежуточных соединений в его производстве и составам, содержащим псилоцибин.The invention relates to the large-scale production of psilocybin for use in medicine. More specifically, it relates to a process for the production of high purity crystalline psilocybin, in particular in the form of polymorph A. It also relates to a process for the production of psilocybin and intermediates in its production and compositions containing psilocybin.

EA202090917A 2017-10-09 2018-10-09 OBTAINING PSILOCYBIN, DIFFERENT POLYMORPHOUS FORMS, INTERMEDIATE COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION EA202090917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1716505.1A GB2571696B (en) 2017-10-09 2017-10-09 Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
PCT/IB2018/057811 WO2019073379A1 (en) 2017-10-09 2018-10-09 Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB1816438.4A GB2576059B (en) 2017-10-09 2018-10-09 A pharmaceutical formulation comprising psilocybin

Publications (1)

Publication Number Publication Date
EA202090917A1 true EA202090917A1 (en) 2021-01-14

Family

ID=60326674

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090917A EA202090917A1 (en) 2017-10-09 2018-10-09 OBTAINING PSILOCYBIN, DIFFERENT POLYMORPHOUS FORMS, INTERMEDIATE COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION

Country Status (17)

Country Link
US (10) US10519175B2 (en)
EP (1) EP3694835A1 (en)
JP (3) JP2020536960A (en)
KR (1) KR20200085753A (en)
CN (1) CN111491919A (en)
AU (2) AU2018349279B2 (en)
BR (1) BR112020006947A2 (en)
CA (1) CA3078765A1 (en)
CO (1) CO2020005643A2 (en)
DE (1) DE202018006384U1 (en)
EA (1) EA202090917A1 (en)
GB (4) GB2571696B (en)
IL (1) IL273883B1 (en)
MX (1) MX2020003910A (en)
PH (1) PH12020550246A1 (en)
SG (1) SG11202003198RA (en)
WO (1) WO2019073379A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346346A1 (en) 2017-02-09 2021-11-11 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
US11974984B2 (en) * 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
DE102019117739A1 (en) 2019-07-01 2021-01-07 Felix Blei Arylalkylamine, pyrrole, indole, and opiate derivative concentration methods and test kits using this method
KR20220092509A (en) 2019-10-01 2022-07-01 엠피리언 뉴로사이언스, 인크. Genetic Engineering of Fungi to Regulate Tryptamine Expression
PL3844147T3 (en) 2019-11-07 2022-07-18 Small Pharma Ltd Compounds
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
JP2023513680A (en) 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド Silosine derivatives as serotonergic hallucinogens for the treatment of central nervous system disorders
US11332441B2 (en) * 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
IL299448A (en) 2020-06-17 2023-02-01 Psilo Scient Ltd Process for Obtaining a Purified Psychoactive Alkaloid Solution
CA3123908C (en) * 2020-06-17 2022-03-22 Psilo Scientific Ltd. Ethanol extraction of psychoactive compounds from psilocybin fungus
US11382942B2 (en) 2020-06-17 2022-07-12 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
US11510952B2 (en) 2020-06-17 2022-11-29 Psilo Scientific Ltd. Ethanol extraction of psychoactive compounds from psilocybin fungus
CA3186854A1 (en) * 2020-07-24 2022-01-27 Mindset Pharma Inc. Scalable synthetic route for psilocin and psilocybin
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
CA3193308A1 (en) 2020-10-21 2022-04-28 Compass Pathfinder Limited Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
WO2022094054A1 (en) * 2020-10-28 2022-05-05 Mydecine Innovations Group Inc. Novel fungal compound formulations and their therapeutic methods of use
WO2022117359A1 (en) 2020-12-01 2022-06-09 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2022123232A1 (en) * 2020-12-07 2022-06-16 Beckley Psytech Limited Pharmaceutical composition comprising psilocybin or its polymorphs
CA3197443A1 (en) 2020-12-28 2022-06-28 Psilo Scientific Ltd. Processes for extracting psychoactive alkaloids and preparation thereof into transmucosal forms
US20240059653A1 (en) * 2020-12-31 2024-02-22 1280225 B.C. Ltd. Method of synthesizing indole compounds
US20230416200A1 (en) * 2021-01-11 2023-12-28 Caamtech, Inc. Quaternary tryptamines and their therapeutic uses
EP4291179A1 (en) * 2021-02-10 2023-12-20 Eleusis Therapeutics US, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2022204323A1 (en) * 2021-03-24 2022-09-29 The Trustees Of Columbia University In The City Of New York Non-hallucinogenic ariadne analogs for treatment of neurological and psychiatric disorders
KR20230175186A (en) 2021-03-30 2023-12-29 컴퍼스 패쓰파인더 리미티드 Psilocybin compositions, methods of making and using the same
CA3218165A1 (en) * 2021-05-07 2022-11-10 Canna-Chemistries Llc New crystalline polymorphic form of psilocin
WO2022243285A1 (en) 2021-05-17 2022-11-24 Cybin Irl Limited Formulations of psilocybin
WO2022261263A1 (en) 2021-06-08 2022-12-15 Gilgamesh Pharmaceuticals, Inc. Methods of treating neuropsychiatric disorders
WO2022272176A1 (en) * 2021-06-25 2022-12-29 Synaptive Therapeutics, Llc Psilocybin analogs for treating psychological disorders
EP4366731A2 (en) 2021-07-07 2024-05-15 Terran Biosciences, Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
CN113648320A (en) * 2021-08-16 2021-11-16 中国人民解放军军事科学院军事医学研究院 Medical application of siloxibin in resisting post-traumatic stress disorder
US11344564B1 (en) * 2021-08-20 2022-05-31 Lennham Pharmaceuticals, Inc. Method of treatment based on reduced monoamine oxidase a activity
CA3231520A1 (en) * 2021-09-14 2023-03-23 Matthew Alexander James Duncton Processes of preparing psilocin and psilocybin
CA3237988A1 (en) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
WO2023105222A1 (en) * 2021-12-07 2023-06-15 Beckley Psytech Limited Pharmaceutical composition
WO2023114097A1 (en) 2021-12-13 2023-06-22 Compass Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
WO2023147424A1 (en) * 2022-01-27 2023-08-03 Terran Biosciences, Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine
US11746087B1 (en) 2022-03-18 2023-09-05 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
WO2023173229A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
WO2023225186A1 (en) * 2022-05-18 2023-11-23 Chemtor, Lp Extraction of psilocybin and psilocin
WO2023247665A1 (en) 2022-06-22 2023-12-28 Cybin Irl Limited Solid dispersions of psilocybin
US11667607B1 (en) * 2022-06-30 2023-06-06 Zylorion Health Inc. Crystalline forms of compositions comprising psilocin and psilocybin
US20240002338A1 (en) * 2022-06-30 2024-01-04 Zylorion Health Inc. Crystalline forms of compositions comprising psilocin and psilocybin
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (495)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA672478A (en) * 1963-10-15 Heim Roger Psilocybin and psilocin
LU36879A1 (en) 1958-02-21
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
US3075992A (en) * 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
NL243249A (en) * 1958-09-12
US3192111A (en) * 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
IE24138L (en) 1959-02-18 1959-08-21 Sandoz Ag Psilocybin and psilocin
JPS5576859A (en) 1978-12-01 1980-06-10 Fujimoto Seiyaku Kk Novel preparation of 4-hydroxyindole
US4283709A (en) 1980-01-29 1981-08-11 Summit Systems, Inc. (Interscience Systems) Cash accounting and surveillance system for games
JPS5728046A (en) 1980-07-28 1982-02-15 Nissan Chem Ind Ltd Preparation of 4-substituted indole
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
EP0152379A3 (en) 1984-02-15 1986-10-29 Ciba-Geigy Ag Process for preparing pharmaceutical compositions containing unilamellar liposomes
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
IL76591A0 (en) 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
AU597908B2 (en) 1985-10-04 1990-06-14 Implico B.V. A protein reagent having the ability to bind tissue plasminogen activator in its two chain form and/or its single chain form
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
AU645966B2 (en) 1989-09-05 1994-02-03 University Of Utah Research Foundation Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5935925A (en) 1990-05-08 1999-08-10 Synaptic Pharmaceutical Corporation Methods of treating migraine and compounds useful for such methods
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
AU665933B2 (en) 1990-10-19 1996-01-25 New York University A method for transplanting cells into the brain and therapeutic uses therefor
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
FR2675504B1 (en) 1991-04-16 1995-01-27 Delalande Sa DERIVATIVES OF ARYL-3 OXAZOLIDINONE, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS.
US5468486A (en) 1992-01-21 1995-11-21 The University Of Tennessee Research Corporation Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis
EP0566135A1 (en) 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
CA2125288C (en) 1992-12-24 2004-11-23 Sergio Mantegani Serotoninergic ergoline derivatives
ES2068762B1 (en) 1993-07-21 1995-12-01 Lipotec Sa A NEW PHARMACEUTICAL PREPARATION TO IMPROVE THE BIOAVAILABILITY OF DRUGS OF DIFFICULT ABSORPTION AND PROCEDURE FOR THEIR OBTAINING.
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US20060019963A1 (en) 1994-06-17 2006-01-26 Smithkline Beecham Corporation Compounds
MX9701430A (en) 1994-07-25 1997-12-31 Nda Int Inc A method of treating chemical dependency in mammals and a composition therefor.
US5874477A (en) 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
US5696125A (en) 1995-02-24 1997-12-09 Research Foundation Of The State University Of New York Substance abuse-induced hemorrhagic stoke in an animal model
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
EP0778768B1 (en) 1995-06-09 2004-05-26 Euroceltique S.A. Formulations and methods for providing prolonged local anesthesia
US5879690A (en) 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
DE19542281C2 (en) 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Use of Epinastin for the treatment of migraines
FR2744362B1 (en) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE
FR2744363B1 (en) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa APPLICATION OF THIAZOLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIA OR EXCESSIVE USE
FR2744361B1 (en) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE
FR2744364B1 (en) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa APPLICATION OF UREIDOACETAMIDES TO THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
TW448171B (en) 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5804592A (en) 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
AU743788B2 (en) 1997-05-07 2002-02-07 Unimed Pharmaceuticals, Inc. Method of improving disturbed behavior and elevating mood in humans
WO1998059234A1 (en) 1997-06-24 1998-12-30 The University Of Wyoming Method and apparatus for detection of a controlled substance
GB9715082D0 (en) 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20010004644A1 (en) 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
WO1999009828A1 (en) 1997-08-25 1999-03-04 Pentech Pharmaceuticals, Inc. Method for amelioration of social phobia
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
AU754088B2 (en) 1997-09-04 2002-11-07 Demerx, Inc. Noribogaine in the treatment of pain and drug addiction
DE19738855C2 (en) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermal therapeutic system with adhesive reservoir layer and unidirectional elastic back layer
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
JP2001520999A (en) 1997-10-28 2001-11-06 アシビ， エルエルシー Treatment of sexual dysfunction in women
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
ITTO980264A1 (en) 1998-03-26 1999-09-26 Silvio Rossi APPLICATION OF A NON-QUATERNARY BASIC EXTRACT OF FUCHSIAEFOLIA PESCHIERA WITH ANTI-MALARICA ACTIVITY
EP1089736A2 (en) 1998-06-22 2001-04-11 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
WO2000003679A2 (en) 1998-07-14 2000-01-27 Adams Food Ltd. Nutritionally active composition for hardening fingernails
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
JP2002520353A (en) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー Compositions for the treatment of stress
CA2338326A1 (en) 1998-07-31 2000-02-10 Seth Lederman Use of moclobemide and metabolites for treating and preventing substance abuse
US6664286B1 (en) 1998-09-18 2003-12-16 Alcon Manufacturing, Ltd. Serotonergic 5ht2 agonists for treating glaucoma
US20060025387A1 (en) 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
WO2000044353A1 (en) 1999-01-29 2000-08-03 Losan Pharma Gmbh Pharmaceutical compositions
DK1158973T3 (en) 1999-02-24 2005-05-30 Univ Cincinnati Use of sulfamate derivatives to treat impulse control aberrations
CA2368187A1 (en) 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
JP2002541092A (en) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド Pharmaceutical dosage forms for pulsatile delivery of methylphenidate
ID30355A (en) 1999-04-07 2001-11-22 Pfizer Prod Inc USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPY
US6126924A (en) 1999-05-27 2000-10-03 Scales-Medeiros; Virginia A. Light responsive self-tanning products and methods for use
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
MXPA02001882A (en) 1999-08-23 2002-08-20 Univ Tulane Modulation of the blood brain barrier transporter for leptin.
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
WO2001026642A2 (en) 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
ES2162746B1 (en) 1999-10-21 2003-02-16 Lipotec Sa MICROCAPSULES FOR THE STABILIZATION OF COSMETIC, PHARMACEUTICAL OR FOOD PRODUCTS.
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
KR20020081260A (en) 2000-01-18 2002-10-26 밸리 포지 파마슈티컬즈, 인크. Ocular Growth and Nicotinic Antagonists
FR2804603B1 (en) 2000-02-04 2004-01-23 Rhodia Chimie Sa CONTINUOUS PROCESS FOR FORMULATING IN THE FORM OF GRANULES ONE OR MORE PHARMACEUTICAL ACTIVE SUBSTANCES
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
AU2001243369A1 (en) 2000-03-14 2001-09-24 Massachusetts Institute Of Technology Composition and method to treat weight gain and obesity attributable to psychotropic drugs
EP1278774A2 (en) 2000-03-27 2003-01-29 PE Corporation (NY) Human g-protein coupled receptors
DE10014588A1 (en) 2000-03-27 2001-10-04 Basf Ag Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone
US6380176B2 (en) 2000-03-28 2002-04-30 Ajinomoto Co., Inc. Method for inhibiting non-intentional behavior with a running neuron inhibitory substance
DE10018834A1 (en) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
AU6106801A (en) 2000-04-28 2001-11-12 Gary W. Neal Trans-clitoral administration of therapy
NZ522896A (en) 2000-05-10 2004-05-28 Skyepharma Canada Inc Media milling
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
CA2416650C (en) 2000-07-19 2010-09-21 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
US7229784B2 (en) 2000-09-19 2007-06-12 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
US9399050B2 (en) 2000-10-04 2016-07-26 Paul Edward Stamets Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi
US9474776B2 (en) 2000-10-04 2016-10-25 Paul Edward Stamets Integrative fungal solutions for protecting bees
US20070099999A1 (en) 2000-11-01 2007-05-03 Epstein Mel H Methods of treating depression
US20030119884A1 (en) 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR031473A1 (en) 2000-11-20 2003-09-24 Lundbeck & Co As H GABA INTENSIFIERS IN THE TREATMENT OF DISEASES RELATED TO A REDUCED NEUROSTEROID ACTIVITY
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
WO2002043762A2 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
EP1337272A2 (en) 2000-11-30 2003-08-27 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20020137785A1 (en) 2001-03-26 2002-09-26 George Kindness Inflammatory mechanism modulator composition and methods with anti-asthmatic properties
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CA2443050A1 (en) 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US20040132780A1 (en) 2001-05-04 2004-07-08 Allen Christopher P. Method and compositions for treating migraines
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20040023952A1 (en) 2001-06-20 2004-02-05 Leventhal Audie G. Enhanced brain function by gaba-ergic stimulation
AU2002332942A1 (en) 2001-08-20 2003-03-03 Greiner Bio-One Gmbh Device and method for determining an analyte
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
WO2003020242A1 (en) 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
CN1558756A (en) 2001-09-27 2004-12-29 �ź㴫 Pharmaceutical compositions for the treatment of urinary disorders
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US20060264508A1 (en) 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
US20030082225A1 (en) 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
EP1453468A4 (en) 2001-11-09 2005-11-23 Chiron Corp Method of vaccinating a human patient to prevent metastatic tumors
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-aminoquinoline compounds
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
EP1509204A4 (en) 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030171435A1 (en) 2002-01-23 2003-09-11 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
US7241797B2 (en) 2002-01-23 2007-07-10 University Of Cincinnati Method of increasing milk production
JP4174426B2 (en) 2002-02-07 2008-10-29 ファルマシア コーポレーション Pharmaceutical tablets
PT1471890E (en) 2002-02-07 2007-01-31 Pharmacia Corp Pharmaceutical dosage form for mucosal delivery
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7223735B2 (en) 2003-05-29 2007-05-29 New River Pharmaceuticals Inc. Abuse resistant lysine amphetamine compounds
DE10208335A1 (en) 2002-02-27 2003-09-04 Roehm Gmbh Pharmaceutical form and process for its preparation
US20030199439A1 (en) 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
US20030232805A1 (en) 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
AU2003228654A1 (en) 2002-04-29 2003-11-17 The General Hospital Corporation Compositions and methods for preventing abuse of orally administered medications
AUPS317102A0 (en) 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
JP2005537244A (en) 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Compositions and methods for modulating physiological function of epithelial junction adhesion molecules for enhancing mucosal delivery of therapeutic compounds
US20040006043A1 (en) 2002-07-02 2004-01-08 Ramot University Authority For Applied Research & Industrial Development Ltd. Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
CA2489410C (en) 2002-07-17 2015-01-13 Cytos Biotechnology Ag Molecular antigen arrays
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
JPWO2004014429A1 (en) 2002-08-09 2005-12-02 三菱ウェルファーマ株式会社 Psychiatric disorder vulnerability control agent
US20030114512A1 (en) 2002-09-09 2003-06-19 Collier Robert J Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
AU2003278832A1 (en) 2002-09-13 2004-04-30 Carnegie Mellon University Optical biosensors and methods of use thereof
WO2004026290A1 (en) 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
DE10244504A1 (en) 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Quick-release dosage form with poorly soluble active ingredient
WO2004032900A1 (en) 2002-10-11 2004-04-22 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7132122B2 (en) 2002-10-30 2006-11-07 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using UV light and selected uses thereof
DE10250944B9 (en) 2002-10-31 2004-09-16 Cell Center Cologne Gmbh Use a pen to apply care or active ingredients to the nose
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20060135403A1 (en) 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
ES2314362T3 (en) 2003-01-16 2009-03-16 Acadia Pharmaceuticals Inc. SELECTIVE INVESTING AGONISTS OF SEROTONINE 2A OR 2C RECEPTORS USED AS THERAPEUTIC AGENTS AGAINST NEURODEGENERATIVE DISEASES.
JP2006515628A (en) 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド Use of N-desmethylclozapine to treat human neuropsychiatric disorders
US20040186155A1 (en) 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
AU2004222307B2 (en) 2003-03-17 2008-04-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
WO2004084940A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
EP1635815A4 (en) 2003-06-03 2009-03-25 Beth Israel Hospital Methods and compounds for the treatment of vascular stenosis
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
JP4174016B2 (en) 2003-07-11 2008-10-29 株式会社ビーエル Immunochromatographic detection method and test kit for thylosins by competitive method
DE10334188B4 (en) 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
DE10338174A1 (en) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease
US20050203011A1 (en) 2003-09-19 2005-09-15 The Regents Of The University Of California Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity
US20050070501A1 (en) 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
DE60336934D1 (en) 2003-10-03 2011-06-09 Veijlen N V USE OF IGF-1 SERUM MIRROR-INCREASING INDOLIC ACID DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS DISEASES
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
CA2585024A1 (en) 2003-10-24 2005-05-06 Azopax Therapeutics Llc Macromer-melt formulations
US20070053954A1 (en) 2003-10-24 2007-03-08 Rowe Stephen C Macromer-melt formulations
JP2005132747A (en) 2003-10-29 2005-05-26 Ajinomoto Co Inc Aged pet ageing behavior-improving agent
CN1917876A (en) 2003-12-16 2007-02-21 Cns生物有限公司 Methods and compositions
US20050260258A1 (en) 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
JP2007516275A (en) 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク Therapeutic combinations for cognitive enhancement and psychotic disorders
GB0400802D0 (en) 2004-01-14 2004-02-18 Daniolabs Ltd Compounds for the treatment of disease
WO2005072705A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
EP1734920A2 (en) 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
CA2556214A1 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
WO2005082277A1 (en) 2004-02-18 2005-09-09 Stanford University Drug delivery systems using mesoporous oxide films
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
FR2867075B1 (en) 2004-03-03 2006-07-14 Ethypharm Sa PROCESS FOR PREPARING CALIBRATED BIODEGRADABLE MICROSPHERES
CA2559207A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2567249A1 (en) 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
RU2253461C1 (en) 2004-04-30 2005-06-10 Общество с ограниченной ответственностью "Паркинфарм" Pharmaceutical combination influencing central nervous system function; method of correcting conditions associated with dysfunction of central nervous system; pharmaceutical kit; agent assisting therapeutical substances and metabolites to cross blood-brain barrier; and endonasal drug
US20050255091A1 (en) 2004-05-14 2005-11-17 Loomis Gary L Hydrogels for biomedical applications
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US20050265955A1 (en) 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
NL1026634C2 (en) 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychopharmaceutical preparation and active ingredient.
US7799802B2 (en) 2004-08-03 2010-09-21 Institstute of Oriental Medical Science Inc. Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation
US20060030625A1 (en) 2004-08-06 2006-02-09 Cheryle Ram Hart Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
DE602005024850D1 (en) 2004-09-24 2010-12-30 Beth Israel Hospital METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS
US7655691B2 (en) 2004-09-27 2010-02-02 Sard Howard P Indole compounds useful as serotonin selective agents
EP1799264A2 (en) 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
CN101107013A (en) 2004-11-22 2008-01-16 阿纳迪斯有限公司 Bioactive compositions
FR2878161B1 (en) 2004-11-23 2008-10-31 Flamel Technologies Sa ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2878158B1 (en) 2004-11-24 2009-01-16 Flamel Technologies Sa ORAL PHARMACEUTICAL FORM, SOLID MICROPARTICULAR DESIGNED TO PREVENT MEASUREMENT
US7294649B2 (en) 2004-12-17 2007-11-13 Roche Diagnostics Operatins, Inc. Methamphetamine derivatives and conjugates for immunoassay
US8512751B2 (en) 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2594451A1 (en) 2005-01-10 2007-06-14 Smiths Detection Inc. Sampling swab
DE102005004343A1 (en) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Treatment of phantom phenomena
FR2881652B1 (en) 2005-02-08 2007-05-25 Flamel Technologies Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
MX2007011250A (en) 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Crystallization inhibitor and its use in gelatin capsules.
EP1861427B1 (en) 2005-03-23 2012-08-08 BPSI Holdings, LLC. Agglomerated starch compositions
US20090232898A1 (en) 2005-03-28 2009-09-17 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Migraine
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
JP2008535860A (en) 2005-04-08 2008-09-04 ニュー リヴァー ファーマシューティカルズ インク． Abuse-resistant amphetamine prodrug
EP1874356A2 (en) 2005-04-15 2008-01-09 Board of Trustees of Michigan State University Aminergic pharmaceutical compositions and methods
JP2008535610A (en) 2005-04-15 2008-09-04 インターフェース バイオロジクス インコーポレーティッド Methods and compositions for delivering biologically active agents
JP2008538575A (en) 2005-04-22 2008-10-30 ワイス Benzodioxane and benzodioxolane derivatives and their use
WO2007085898A2 (en) 2005-05-06 2007-08-02 Smiths Detection Inc. Improved chemical identification of peroxide-based explosives
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2006131923A2 (en) 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
EP1895987A2 (en) 2005-06-16 2008-03-12 Mohammed Saeed Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
WO2007052289A2 (en) 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070092586A1 (en) 2005-10-26 2007-04-26 Alamo Pharmaceuticals Compositions and methods for the administration psychotropic drugs which modulate body weight
DE102005055866A1 (en) 2005-11-23 2007-05-24 Hte Ag The High Throughput Experimentation Company Continuous reaction of two liquid, mutually immiscible phases especially in Suzuki (hetero)aryl-(hetero)aryl coupling reactions involves flowing components through packed bed reactor
KR20080089653A (en) 2006-01-21 2008-10-07 애보트 게엠베하 운트 콤파니 카게 Dosage form and method for the delivery of drugs of abuse
WO2007092043A2 (en) 2006-02-02 2007-08-16 Medlogics Device Corporation Bioactive material delivery systems comprising sol-gel compositions
US20070203216A1 (en) 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20070190130A1 (en) 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
US20080075789A1 (en) 2006-02-28 2008-03-27 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
CN101460060A (en) 2006-03-01 2009-06-17 特莱斯特拉塔公司 Composition and method for topical treatment of tar-responsive dermatological disorders
FR2898271B1 (en) 2006-03-09 2009-01-16 Pierre Fabre Medicament Sa NOVEL USE OF ANTIHISTAMINE AGENTS FOR PREVENTIVE TREATMENT OR METHOD OF INFLAMMATORY SYNDROMES, IN PARTICULAR THOSE TRIGGED BY TOGA VIRUSES.
JP2009530385A (en) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン Intranasal ketamine for the treatment of depression
WO2006079999A2 (en) 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
US8445016B2 (en) 2006-04-14 2013-05-21 Interface Biologics, Inc. Grafted polymers and uses thereof
GB0608647D0 (en) 2006-05-02 2006-06-14 Haritou Susan J A Methods of diagnosis and treatment
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
BRPI0621633A2 (en) 2006-05-12 2011-12-13 Shire Llc pharmaceutical composition, method for treating attention deficit hyperactivity disorder (ADHD) and sustained release pharmaceutical composition
WO2008003028A2 (en) 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
JP2010501026A (en) 2006-06-30 2010-01-14 インターフェース バイオロジクス，インコーポレーテッド Bioresponsive polymer
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
JP2009543812A (en) 2006-07-20 2009-12-10 キャスケイド・セラピューティクス・インコーポレイテッド Tetrahydro-5H-pyrido [2,3-d] azepine as 5-HT2C ligand
US20080026189A1 (en) 2006-07-27 2008-01-31 Chun-Wei Lin Thin key structure for generating dazzling light
JP5243428B2 (en) 2006-08-23 2013-07-24 ザ ユニヴァーシティ オブ モンタナ Pharmaceutical composition for reducing neuronal damage
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
JP2010502623A (en) 2006-08-31 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Methods for peripheral administration of Nogo receptor polypeptides
EP2066355A2 (en) 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
CA2664935A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
WO2008038291A1 (en) 2006-09-27 2008-04-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
EP2086538B1 (en) 2006-10-27 2012-03-14 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using dimebon and donepezil
CA2667510A1 (en) 2006-10-27 2008-06-12 Janssen Pharmaceutica N.V. Methods for treating disruptive behavior disorders
EP2089011A1 (en) 2006-10-31 2009-08-19 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8653106B2 (en) 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
EP2101571B1 (en) 2006-12-11 2011-05-18 Kempharm, Inc. Ornithine conjugates of amphetamine and processes for making and using the same
ES2302650B1 (en) 2007-01-11 2009-02-16 Tedec-Meiji Farma, S.A. COMPOSITION OF FAST DISINTEGRATION IN THE ORAL CAVITY.
CA2677205A1 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
AU2008213643A1 (en) 2007-02-08 2008-08-14 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
NZ579368A (en) 2007-03-09 2012-03-30 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
US20080227830A1 (en) 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2008115797A1 (en) 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
DE102007014286A1 (en) 2007-03-19 2008-09-25 Universität Tübingen Fluorine-substituted amphetamines and amphetamine derivatives and their use
CA2963423C (en) 2007-03-30 2020-07-28 Philip Morris Products S.A. Device and method for delivery of a medicament
AT505086B1 (en) 2007-04-02 2009-06-15 Planta Naturstoffe Vertriebsge PHARMACEUTICAL AGENT AGAINST JUCKREIZ AND JUCKREIZED PAIN
WO2008122990A1 (en) 2007-04-04 2008-10-16 Almet Corporation Limited Compacting upflow extractor and method of using it
EP2146701B1 (en) 2007-04-12 2013-10-16 Rutgers, The State University of New Jersey Biodegradable polyanhydrides with natural bioactive molecules
PL2172471T3 (en) 2007-04-18 2013-08-30 Teva Pharma A process for preparing intermediates of HMG-CoA reductase inhibitors
US7638651B2 (en) 2007-04-26 2009-12-29 Auspex Pharmaceuticals Substituted cyclohexanones
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
KR20100051829A (en) 2007-07-31 2010-05-18 리머릭 바이오파르마 인코오포레이티드 Phosphorylated pyrone analogs and methods
JP5460594B2 (en) 2007-08-03 2014-04-02 リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ Pharmaceutical composition containing dopamine receptor ligand and method of treatment using dopamine receptor ligand
FR2919861A1 (en) 2007-08-06 2009-02-13 Sanofi Aventis Sa RIMONABANT ISOPRANOL SOLVATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
AU2016208412A1 (en) 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
RU2491067C2 (en) 2007-08-06 2013-08-27 Байотай Терапис, Инк Method of treating addiction
CN101827828B (en) 2007-08-07 2013-02-27 普罗萨里克斯有限公司 1, 2, 4 -triazole derivatives as serotonergic modulators
US8067028B2 (en) 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
CA2701186C (en) 2007-10-05 2017-09-19 Interface Biologics Inc. Oligofluorinated cross-linked polymers and uses thereof
WO2009049215A1 (en) 2007-10-10 2009-04-16 Wake Forest University Health Sciences Methods to reduce the effects of sleep deprivation
WO2009055001A2 (en) 2007-10-23 2009-04-30 Fred Hutchinson Cancer Research Center Methods of treating aging and methods of screening candidate agents therefor
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound
DE102007063210A1 (en) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Medicines for the treatment of phantom phenomena
WO2009079765A1 (en) 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
WO2009089234A2 (en) 2008-01-07 2009-07-16 Auspex Pharmaceuticals Substituted dibenzhydrylpiperazines
ES2620672T3 (en) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Double layer tablets comprising oxycodone and promethazine
WO2009091605A2 (en) 2008-01-17 2009-07-23 Health Innovations, Llc Taste titration therapies
WO2009097596A1 (en) 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
MX2010008024A (en) 2008-02-01 2010-12-21 Ascendis Pharma As Prodrug comprising a self-cleavable linker.
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
WO2009102805A1 (en) 2008-02-11 2009-08-20 Organix Inc. Indole compounds and methods of use thereof
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
EA201001521A1 (en) * 2008-03-26 2011-04-29 Лонца Лтд. METHOD FOR SYNTHESIS OF ETHYNYL CYCLOPROPANE
US20170276676A1 (en) 2008-03-27 2017-09-28 Gus J. Slotman System for assessing drug efficacy and response of a patient to therapy
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
EP2106799A1 (en) 2008-03-31 2009-10-07 OWEN Holding LTD Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
US20090252786A1 (en) 2008-03-31 2009-10-08 Christoph Hanz Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor
FR2930147B1 (en) 2008-04-18 2013-02-08 Flamel Tech Sa SOLID ORAL FORM WITH A DOUBLE RELEASE PROFILE
JP2011518881A (en) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド Formulations for the treatment of migraine
US20110086063A1 (en) 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US10388179B2 (en) 2008-06-18 2019-08-20 Accenture Global Solutions Limited Analytics platform
MX351262B (en) 2008-06-19 2017-10-06 Lts Lohmann Therapie Systeme Ag Star Composition for transdermal delivery of cationic active agents.
WO2010001391A1 (en) 2008-06-30 2010-01-07 Oron Zachar Dermal application of vasoconstrictors
US9642819B2 (en) 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
US8617607B2 (en) 2008-07-10 2013-12-31 Tyrx, Inc. Sustained release formulations of psychoactive drugs
US20110207718A1 (en) 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
FR2935611B1 (en) 2008-09-10 2010-10-15 Commissariat Energie Atomique USE OF ANTI-CONNEXINE AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES
FR2936710B1 (en) 2008-10-07 2011-01-07 Ceva Sante Animale ANTIPROLACTINIC VETERINARY COMPOSITION FOR RUMINANTS
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
UA105657C2 (en) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Enhanced migraine treatments based on anamorelin
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
WO2010123577A2 (en) 2009-04-24 2010-10-28 Galenea Corp. Compositions and methods for evaluating cognitive deficits
CA2763172A1 (en) 2009-05-26 2010-12-02 David Hackett Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US20110306596A1 (en) 2009-07-27 2011-12-15 Auspex Pharmaceuticals, Inc. Benzazepine inhibitors of gamma-secretase
WO2011020030A2 (en) 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
US20110038915A1 (en) 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
US20120171239A1 (en) 2009-09-03 2012-07-05 Mizel Steven B Immunogenic Conjugates for Producing Immune Responses to Drugs of Abuse and Methods of Use
FR2954167A1 (en) 2009-09-04 2011-06-24 Centre Nat Rech Scient OCYTOCINE TREATMENT OF BEHAVIORAL CHARACTERISTICS ASSOCIATED WITH AUTISM AND PATHOLOGICAL TIMIDITY
FR2951378B1 (en) 2009-10-16 2012-06-01 Flamel Tech Sa ANTI-MEASURING SOLID ORAL PHARMACEUTICAL FORM WITH A SPECIFIC MODIFIED RELEASE PROFILE
CN102596278B (en) 2009-10-16 2016-06-29 帝斯曼知识产权资产管理有限公司 Comprise the coating of polyesteramide containing double; two-(alpha-amido-glycol-diester)
EP2490677A2 (en) 2009-10-19 2012-08-29 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
CA3037168A1 (en) 2009-12-18 2011-06-23 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
LT2531200T (en) 2010-02-06 2017-09-25 Grünenthal GmbH Crystallization method and bioavailability
US20110217289A1 (en) 2010-03-05 2011-09-08 Basf Se Melt-Coated Dosage Forms
CA2829180C (en) 2010-03-05 2019-01-15 Newagriculture, Inc. Leaf protein-lipid-soluble material complexes
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011138142A1 (en) 2010-05-07 2011-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and use of sulfasalazine
CN102970967A (en) 2010-05-10 2013-03-13 赛格提斯有限公司 Fragrant formulations, methods of manufacture thereof and articles comprising the same
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
JP2012020991A (en) 2010-06-16 2012-02-02 Takasago Internatl Corp Transdermal absorption promoter, and external skin formulation thereof
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CN103079571A (en) 2010-07-23 2013-05-01 德莫科斯公司 Noribogaine compositions
EP3333185A1 (en) 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US20120129834A1 (en) 2010-09-17 2012-05-24 Buck Institute For Research On Aging Serotonin receptor antagonists for use in the treatment of huntington's disease
US20130197032A1 (en) 2010-09-20 2013-08-01 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
AU2011313814B2 (en) 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
ES2673219T3 (en) 2010-11-15 2018-06-20 Neuroderm Ltd Composition for transdermal delivery of active agents
CN103354902B (en) 2010-12-06 2016-03-02 特拉维夫大学拉玛特有限公司 Drug test method and kit
CA2822738C (en) 2010-12-22 2021-06-08 Exonoid Medical Devices Ltd. Method and system for drug delivery
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
FR2971423B1 (en) 2011-02-15 2014-01-10 Ceva Sante Animale ANTIPROLACTINIC VETERINARY COMPOSITION FOR RUMINANTS
US8742096B2 (en) 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
CN103502817B (en) 2011-03-28 2016-01-20 前视红外系统股份有限公司 Comprise the detection method of the analysis thing of medicine
JOP20120083B1 (en) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
US20120282255A1 (en) 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
KR20120128440A (en) 2011-05-17 2012-11-27 삼성전자주식회사 Kit and method for detecting target material
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
MX2014001933A (en) 2011-09-15 2014-03-27 Demerx Inc Noribogaine salt ansolvates.
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
JP6170932B2 (en) 2011-11-07 2017-07-26 ノバルティス アーゲー Carrier molecule comprising spr0096 antigen and spr2021 antigen
FR2983409B1 (en) 2011-12-06 2013-12-27 Ethypharm Sa COMPRESSOR CAPABLE OF COMBATTING INJECTION MISTAKE
CN104364256A (en) 2011-12-08 2015-02-18 德莫科斯公司 Stereoselective total synthesis of noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
WO2013085849A2 (en) 2011-12-09 2013-06-13 Demerx, Inc. Sulfate esters of noribogaine
EP2607352A1 (en) 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
EP2610245A1 (en) 2011-12-28 2013-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-sulfonamides for treatment of psychiatric disorders
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
WO2013112757A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
WO2013112163A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US20130295170A1 (en) 2012-05-03 2013-11-07 Kydes Pharmaceuticals Llc Compositions for control of drug abuse
US20130295016A1 (en) 2012-05-07 2013-11-07 David J. Gerber Signatures of electroencephalographic oscillations
CN104411316B (en) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 The treatment of bone marrow suppression
US20150196533A1 (en) 2012-07-02 2015-07-16 The General Hospital Corporation Method for concurrent treatment of pain and depression
US8784835B2 (en) 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
US9622971B2 (en) 2012-08-17 2017-04-18 Smartek International Llc Preparation of desiccated liposomes for use in compressible delivery systems
JP6434408B2 (en) 2012-08-24 2018-12-05 インテグアールエックス セラピューティクス， エルエルシーＩｎｔｅｇｕｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
WO2014035473A1 (en) 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014064703A1 (en) 2012-10-28 2014-05-01 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
CN105189492A (en) 2012-11-19 2015-12-23 萨克·W·金 Ergoline derivatives as dopamine receptor modulators
US9737562B2 (en) 2012-12-11 2017-08-22 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
EP2948135B1 (en) 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
US20140294923A1 (en) 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
CN105142611B (en) 2013-03-10 2019-06-04 佩丽泰克医药有限公司 Topical composition and the method for treating topical condition
US20140288454A1 (en) 2013-03-14 2014-09-25 Pulmonary Analytics Method For Using Exhaled Breath to Determine the Presence of Drug
WO2014146082A1 (en) 2013-03-15 2014-09-18 Bhl Patent Holdings Llc Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
WO2014142938A1 (en) 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
KR20210113429A (en) 2013-03-15 2021-09-15 멜리어 파마슈티칼스 투, 엘엘씨. A pharmaceutical composition comprising sydnocarb or a pharmaceutically acceptable salt thereof and method of treating sleep disorders
WO2014143201A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US20160077091A1 (en) 2013-04-26 2016-03-17 Express Diagnostics International, Inc. Portable testing system for detecting selected drugs or compounds in noncontrolled environments
WO2014186623A2 (en) 2013-05-17 2014-11-20 Biomed Valley Discoveries Methods and compositions for the treatment of a chagas disease
JP6466417B2 (en) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング A tamper-resistant dosage form with a bimodal release profile
CA2817728A1 (en) 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
KR101814895B1 (en) 2013-06-04 2018-01-04 바이옴 바이오사이언스 피브이티. 엘티디. Coated particles and compositions comprising same
WO2014197753A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
EP2818177A1 (en) 2013-06-24 2014-12-31 Celica, D.O.O. Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states
CA2916973A1 (en) 2013-07-03 2015-01-08 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
BR112016000338A8 (en) 2013-07-08 2020-01-07 Auspex Pharmaceuticals Inc deuterium-enriched compound of structural formula i, pharmaceutical composition, and uses of a compound
MX368846B (en) 2013-07-12 2019-10-18 Gruenenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer.
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
US9474481B2 (en) 2013-10-22 2016-10-25 Mindstrong, LLC Method and system for assessment of cognitive function based on electronic device usage
US9420970B2 (en) 2013-10-22 2016-08-23 Mindstrong, LLC Method and system for assessment of cognitive function based on mobile device usage
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20160256392A1 (en) 2013-10-31 2016-09-08 Cima Labs Inc. Abuse-deterrent dosage forms
TW201605856A (en) 2013-11-01 2016-02-16 艾尼納製藥公司 5-HT2c receptor agonists
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN103535561A (en) 2013-11-05 2014-01-29 杨剑 Forage feed for raising big pigs
CN103549133A (en) 2013-11-05 2014-02-05 杨剑 Organic forage feed for pigs
CN103751943B (en) 2014-01-13 2020-10-13 湖北及安盾消防科技有限公司 Fire extinguishing composition containing nitrogen-containing organic compound
CN103773056B (en) 2014-01-24 2015-11-18 山东大学 High brittle transparent rock-like materials test material preparation method
EP3096794A2 (en) 2014-01-24 2016-11-30 DemeRx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CA2978537C (en) 2014-03-03 2023-10-24 Demerx, Inc. Therapeutic uses of ibogaine and related compounds
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
WO2015187289A1 (en) 2014-06-03 2015-12-10 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
MX2017001279A (en) 2014-07-30 2017-08-07 Cleveland Biolabs Inc Flagellin compositons and uses.
US10231651B2 (en) 2014-09-25 2019-03-19 Bae Systems Information And Electronic Systems Integration Inc. Gait authentication system and method thereof
US10058253B2 (en) 2014-11-11 2018-08-28 Zenmark, Llc System, method, and article for heart rate variability monitoring
GB201501312D0 (en) 2015-01-27 2015-03-11 Knauf Insulation And Knauf Insulation Llc And Knauf Insulation Gmbh And Knauf Insulation Doo Skofja Melter feeding system
EP3268086A4 (en) 2015-03-10 2018-11-07 Eleusis Benefit Corporation, PBC Lsd for the treatment of alzheimer's disease
US11298326B2 (en) 2015-03-24 2022-04-12 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
US10254298B1 (en) 2015-03-25 2019-04-09 National Technology & Engineering Solutions Of Sandia, Llc Detection of metabolites for controlled substances
WO2016161138A1 (en) 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
EA034446B1 (en) 2015-04-27 2020-02-10 Арена Фармасьютикалз, Инк. 5-htreceptor agonists and compositions and methods of use thereof
WO2016178053A1 (en) 2015-05-01 2016-11-10 Lozinsky Evgenia Compositions for the treatment of epistaxis
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
CA2968703A1 (en) 2015-05-19 2016-11-24 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US9737759B2 (en) 2015-07-17 2017-08-22 Genesant Technologies, Inc. Automatic application-based exercise tracking system and method
BR112018001707A2 (en) 2015-07-31 2018-09-18 Arena Pharm Inc 5-ht2c receptor agonists and compositions and methods of use
US9614734B1 (en) 2015-09-10 2017-04-04 Pearson Education, Inc. Mobile device session analyzer
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
EA038219B1 (en) 2016-08-19 2021-07-26 Арена Фармасьютикалз, Инк. 5-ht2c receptor agonists and compositions and method of use thereof
US10596378B2 (en) 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US20180195455A1 (en) 2017-01-12 2018-07-12 GM Global Technology Operations LLC Engine combustion phasing control during transient state
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US10940163B2 (en) 2017-02-02 2021-03-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
CN110740728A (en) 2017-02-09 2020-01-31 卡马技术有限责任公司 Compositions and methods comprising gymnosporine derivatives
WO2018145219A1 (en) 2017-02-09 2018-08-16 Serani Mostazal Jorge Pharmaceutical composition for preventing and treating addictions by means of aversive counterconditioning
CN108619214A (en) 2017-03-15 2018-10-09 王慎君 A kind of drug for treating tumour
BR112019020554A2 (en) 2017-03-30 2020-04-28 Ojai Energetics Pbc methods and compositions to improve health conditions
CN111212837A (en) 2017-04-07 2020-05-29 艾森医药公司 Pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase inhibitors and methods of making the same
WO2018195455A1 (en) 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US20180343812A1 (en) 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
US20190246591A1 (en) 2017-05-31 2019-08-15 Insectergy, Llc Insect and cannabis production systems and methods
JP2020522693A (en) 2017-06-02 2020-07-30 ノースウェスタン ユニヴァーシティＮｏｒｔｈｗｅｓｔｅｒｎ Ｕｎｉｖｅｒｓｉｔｙ Thin flexible skin-worn microfluidic network for detection and analysis of focused targets in sweat
CN107252080A (en) 2017-07-12 2017-10-17 沈建国 A kind of formula of numb mushroom sauce
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2021500948A (en) 2017-10-19 2021-01-14 エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド Methods and systems to improve the safety of psychedelic drug therapy
WO2019081764A1 (en) 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Combination product for the treatment of neurological and/or psychiatric disorders
WO2019099745A1 (en) 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
US10703325B2 (en) 2017-11-27 2020-07-07 Autoliv Asp, Inc. Multi-chambered side airbag assemblies
EP3720506A4 (en) 2017-12-04 2021-09-29 Lecouteur, David Compositions and methods for modulating liver endothelial cell fenestrations
FI128750B (en) 2017-12-21 2020-11-30 Helsingin Yliopisto Methods for determining the therapeutic efficacy of rapid-acting antidepressants and personalized antidepressant therapy related thereto
WO2019144140A1 (en) 2018-01-22 2019-07-25 CyPhi LLC Bio-mimetic formulation
WO2019161050A1 (en) 2018-02-18 2019-08-22 Akili Interactive Labs, Inc. Cognitive platform including computerized elements coupled with a therapy for mood disorder
JP2021514682A (en) 2018-03-08 2021-06-17 ニュー アトラス バイオテクノロジーズ エルエルシー How to produce tryptamine
FI129102B (en) 2018-03-19 2021-07-15 Teknologian Tutkimuskeskus Vtt Oy Heterologous production of psilocybin
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
WO2020041329A1 (en) 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases
WO2020053196A1 (en) 2018-09-10 2020-03-19 Universität Basel Method for the biocatalytic alkylation of a substrate
CN117065177A (en) 2019-01-04 2023-11-17 阿波罗神经科学公司 System and method for wave generation for percutaneous vibration
KR20210134313A (en) 2019-01-30 2021-11-09 다이아몬드 테라퓨틱스 인크. Compositions and methods comprising 5HT receptor agonists for the treatment of psychological, cognitive, behavioral and/or mood disorders
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
KR20230175186A (en) 2021-03-30 2023-12-29 컴퍼스 패쓰파인더 리미티드 Psilocybin compositions, methods of making and using the same

Also Published As

Publication number Publication date
GB2571696A (en) 2019-09-11
GB2576059B (en) 2022-06-29
GB2588506B (en) 2022-07-06
JP2024069473A (en) 2024-05-21
US11939346B2 (en) 2024-03-26
AU2018349279B2 (en) 2023-09-21
US20230250115A1 (en) 2023-08-10
GB2588506A (en) 2021-04-28
GB202012914D0 (en) 2020-09-30
AU2018349279A1 (en) 2020-05-28
SG11202003198RA (en) 2020-05-28
GB2572023C2 (en) 2022-09-07
GB2576059A (en) 2020-02-05
US20200199161A1 (en) 2020-06-25
US20210246152A1 (en) 2021-08-12
US11851451B2 (en) 2023-12-26
US10947257B2 (en) 2021-03-16
US11149044B2 (en) 2021-10-19
GB2572023C (en) 2022-02-02
WO2019073379A1 (en) 2019-04-18
US20220073548A1 (en) 2022-03-10
MX2020003910A (en) 2020-11-06
GB2571696B (en) 2020-05-27
US20210087212A1 (en) 2021-03-25
PH12020550246A1 (en) 2021-02-15
CN111491919A (en) 2020-08-04
US10519175B2 (en) 2019-12-31
AU2023285799A1 (en) 2024-01-18
DE202018006384U1 (en) 2020-03-19
US20200331939A1 (en) 2020-10-22
JP2020536960A (en) 2020-12-17
GB2572023A (en) 2019-09-18
US11180517B2 (en) 2021-11-23
US11447510B2 (en) 2022-09-20
US11629159B2 (en) 2023-04-18
US11505564B2 (en) 2022-11-22
BR112020006947A2 (en) 2020-10-06
US20190119310A1 (en) 2019-04-25
KR20200085753A (en) 2020-07-15
IL273883B1 (en) 2024-05-01
IL273883A (en) 2020-05-31
US20220402949A1 (en) 2022-12-22
GB201810588D0 (en) 2018-08-15
US20210155642A1 (en) 2021-05-27
JP2023024755A (en) 2023-02-16
CA3078765A1 (en) 2019-04-18
US10954259B1 (en) 2021-03-23
CO2020005643A2 (en) 2020-05-15
US20230119714A1 (en) 2023-04-20
GB201716505D0 (en) 2017-11-22
EP3694835A1 (en) 2020-08-19
GB201816438D0 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
EA202090917A1 (en) OBTAINING PSILOCYBIN, DIFFERENT POLYMORPHOUS FORMS, INTERMEDIATE COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION
MX2019012942A (en) Fused imidazo-piperidine jak inhibitor compound.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
EA201890752A1 (en) METHOD OF OBTAINING ANTI-FIBER CONNECTIONS
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
CL2018002089A1 (en) Tlr7 agonist maleate, its crystalline forms c, d and e, its preparation processes and its use
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
BR112018073490A2 (en) 6.7.steroid beta-epoxides as chemical intermediates
EA201990688A1 (en) POLYMORPHIC FORMS OF COMPOUNDS REPRESENTING A KINASE INHIBITOR CONTAINING THEIR PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THEIR AND THEIR APPLICATION
EP3795578A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
EA202090980A1 (en) SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGUES
EA201792425A1 (en) TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS PHOSPHODYSTERASE INHIBITORS
EA201391721A1 (en) METHOD OF OBTAINING POLYMORPHIC FORM I ETHORIKOXIB
MY176613A (en) Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue
MX2019009242A (en) A novel process for the synthesis of 1-aryl-1-trifluoromethylcycl opropanes.
WO2015128882A3 (en) Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
EA201990362A1 (en) ANALOGUE OF VORTIOXETINE AND ITS APPLICATION AND OBTAINING
EA202190330A1 (en) METHOD FOR OBTAINING POLYMORPHIC FORM OF ROBENACOXIB
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin
AR100095A1 (en) SOLID FORMS OF ACID {[(2R, 3S, 4R, 5S) -4- (4-CHLORO-2-FLUORO-PHENYL) -3- (3-CHLORO-2-FLUORO-PHENYL) -4-CIANO-5- (2,2-DIMETIL-PROPIL) -PIRROLIDIN-2-CARBONIL] -AMINO} -3-METOXI-BENZOICO
IN2014CH00444A (en)
IN2015CH02092A (en)
EA201791098A1 (en) METHOD FOR SYNTHESIS OF BENZAZEPIN DERIVATIVES
IN2014MU00565A (en)